SPD-502 (sodium)
SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity[1].
Product Specifications
CAS Number
[205645-02-9]
Product Name Alternative
NS-1209 (sodium)
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
IGluR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/spd-502-sodium.html
Smiles
O=C(C(CCO)O/N=C1C(NC2=C(CN(CC3)C)C3=C(C4=CC=C(S(=O)(N(C)C)=O)C=C4)C=C2\1)=O)O[Na]
Molecular Formula
C24H27N4NaO7S
Molecular Weight
538.55
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]SPD-502: A Water-Soluble and In Vivo Long-Lasting Ampa Antagonist with Neuroprotective Activity
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human DLX4 shRNA (UAS) - Lentiviral human DLX4 shRNA (UAS, GFP) plasmid
